X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs TORRENT PHARMA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES TORRENT PHARMA PIRAMAL ENTERPRISES/
TORRENT PHARMA
 
P/E (TTM) x 7.6 45.5 16.7% View Chart
P/BV x 1.4 6.2 22.0% View Chart
Dividend Yield % 1.2 0.8 144.4%  

Financials

 PIRAMAL ENTERPRISES   TORRENT PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-18
TORRENT PHARMA
Mar-18
PIRAMAL ENTERPRISES/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs3,0831,550 198.9%   
Low Rs1,9021,144 166.3%   
Sales per share (Unadj.) Rs589.7354.7 166.3%  
Earnings per share (Unadj.) Rs284.040.1 708.8%  
Cash flow per share (Unadj.) Rs310.564.2 483.5%  
Dividends per share (Unadj.) Rs25.0014.00 178.6%  
Dividend yield (eoy) %1.01.0 96.5%  
Book value per share (Unadj.) Rs1,467.0273.1 537.1%  
Shares outstanding (eoy) m180.27169.22 106.5%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x4.23.8 111.3%   
Avg P/E ratio x8.833.6 26.1%  
P/CF ratio (eoy) x8.021.0 38.3%  
Price / Book Value ratio x1.74.9 34.5%  
Dividend payout %8.834.9 25.2%   
Avg Mkt Cap Rs m449,332227,897 197.2%   
No. of employees `0006.814.7 46.6%   
Total wages/salary Rs m19,88111,353 175.1%   
Avg. sales/employee Rs Th15,535.64,083.0 380.5%   
Avg. wages/employee Rs Th2,905.4772.3 376.2%   
Avg. net profit/employee Rs Th7,482.5461.3 1,622.0%   
INCOME DATA
Net Sales Rs m106,31060,021 177.1%  
Other income Rs m2,5952,988 86.8%   
Total revenues Rs m108,90663,009 172.8%   
Gross profit Rs m51,59913,493 382.4%  
Depreciation Rs m4,7734,086 116.8%   
Interest Rs m29,7833,085 965.5%   
Profit before tax Rs m19,6389,310 210.9%   
Minority Interest Rs m2,8010-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-28,7642,529 -1,137.5%   
Profit after tax Rs m51,2036,781 755.0%  
Gross profit margin %48.522.5 215.9%  
Effective tax rate %-146.527.2 -539.3%   
Net profit margin %48.211.3 426.3%  
BALANCE SHEET DATA
Current assets Rs m118,15452,623 224.5%   
Current liabilities Rs m462,26052,022 888.6%   
Net working cap to sales %-323.71.0 -32,298.5%  
Current ratio x0.31.0 25.3%  
Inventory Days Days27120 22.2%  
Debtors Days Days4776 61.1%  
Net fixed assets Rs m113,72785,016 133.8%   
Share capital Rs m361846 42.6%   
"Free" reserves Rs m264,09345,376 582.0%   
Net worth Rs m264,45446,222 572.1%   
Long term debt Rs m242,20641,115 589.1%   
Total assets Rs m726,834142,432 510.3%  
Interest coverage x1.74.0 41.3%   
Debt to equity ratio x0.90.9 103.0%  
Sales to assets ratio x0.10.4 34.7%   
Return on assets %11.16.9 160.9%  
Return on equity %19.414.7 132.0%  
Return on capital %10.314.2 72.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,11014,580 103.6%   
Fx outflow Rs m4,2983,600 119.4%   
Net fx Rs m10,81310,980 98.5%   
CASH FLOW
From Operations Rs m-159,6668,942 -1,785.6%  
From Investments Rs m-17,677-47,070 37.6%  
From Financial Activity Rs m186,50334,174 545.7%  
Net Cashflow Rs m9,364-3,655 -256.2%  

Share Holding

Indian Promoters % 52.9 71.5 74.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 7.0 57.0%  
FIIs % 26.6 12.6 211.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 8.8 187.5%  
Shareholders   93,274 26,511 351.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 190 Points Higher; Consumer Durable and Healthcare Stocks Witness Buying(Closing)

After trimming sharp losses in the afternoon session, Indian share markets continued to witness buying interest and ended the day on a positive note.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Dec 11, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS